Patents by Inventor Kai W. Wucherpfennig

Kai W. Wucherpfennig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS
    Publication number: 20240092904
    Abstract: The present invention is based, in part, on the identification of novel biomarkers, and methods of modulate thereof, for sensitizing cancer cells to T cell-mediated killing.
    Type: Application
    Filed: August 15, 2023
    Publication date: March 21, 2024
    Inventors: Deng Pan, Kai W. Wucherpfennig
  • Methods and Compositions for Reducing Immunosupression by Tumor Cells
    Publication number: 20230383298
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Application
    Filed: January 3, 2023
    Publication date: November 30, 2023
    Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
    Patent number: 11820822
    Abstract: The present invention is based, in part, on the identification of biomarkers, and methods of modulate thereof, for sensitizing cancer cells to T cell-mediated killing. For example, the present invention, in part, comprises methods of sensitizing cancer cells in a subject afflicted with a cancer to cytotoxic T cell-mediated killing comprising administering to a subject a therapeutically effective amount of an agent that modulates the biomarker.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: November 21, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Deng Pan, Kai W. Wucherpfennig
  • Methods and compositions for reducing immunosuppression by tumor cells
    Patent number: 11597934
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: March 7, 2023
    Assignees: DANA FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Compositions and methods for inhibition of MICA/B shedding
    Patent number: 11421032
    Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies, and antigen-binding fragments thereof, that specifically bind to MICA/B ?3 domain, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 23, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Lucas Ferrari de Andrade, Kai W. Wucherpfennig
  • VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER
    Publication number: 20210299186
    Abstract: The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC alpha 3-domain polypeptide.
    Type: Application
    Filed: February 19, 2021
    Publication date: September 30, 2021
    Inventors: Kai W. Wucherpfennig, Soumya Badrinath
  • Methods and Compositions for Reducing Immunosupression by Tumor Cells
    Publication number: 20210139914
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 13, 2021
    Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Vaccination with MICA/B alpha 3 domain for the treatment of cancer
    Patent number: 10993971
    Abstract: The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against an MIC alpha 3-domain polypeptide.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: May 4, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kai W. Wucherpfennig, Soumya Badrinath
  • Methods and compositions for reducing immunosupression by tumor cells
    Patent number: 10876120
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: December 29, 2020
    Assignees: DANA-FARBER CANCER INSTITUTE, INC, THE GENERAL HOSPITAL CORPORATION
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Therapeutic peptides
    Patent number: 10793633
    Abstract: The present disclosure provides, in part, compositions comprising peptides that immunospecifically bind to a defined binding partner, such as MHC class I polypeptide-related sequence A (MICA), or an epitope thereon. In some embodiments, the peptides comprise one or more complementarity determining regions relating to the complementarity regions shown in Table 1. The disclosure also provides methods of treating cancer in a subject using the compositions disclosed herein, and methods of isolating human antibodies from cancer patients following immunotherapy.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 6, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kai W. Wucherpfennig, Bettina Franz, Kenneth F. May, Jr., Glenn Dranoff, F. Stephen Hodi, Christopher Harvey
  • Therapeutic peptides
    Patent number: 10745483
    Abstract: The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 18, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, F. Stephen Hodi, Bettina Franz, Kenneth F. May, Jr., Christopher Harvey
  • METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS
    Publication number: 20200095320
    Abstract: The present invention is based, in part, on the identification of novel biomarkers, and methods of modulation thereof, for sensitizing cancer cells to T cell-mediated killing.
    Type: Application
    Filed: June 5, 2018
    Publication date: March 26, 2020
    Inventors: Deng Pan, Kai W. Wucherpfennig
  • Vaccine compositions and methods for restoring NKG2D pathway function against cancers
    Patent number: 10279021
    Abstract: The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: May 7, 2019
    Assignee: Dana-Faber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Kai W Wucherpfennig, Christopher Harvey, F. Stephen Hodi
  • VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER
    Publication number: 20180353581
    Abstract: The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against an MIC alpha 3-domain polypeptide.
    Type: Application
    Filed: December 5, 2016
    Publication date: December 13, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Kai W. WUCHERPFENNIG, Soumya BADRINATH
  • Methods and Compositions for Reducing Immunosupression by Tumor Cells
    Publication number: 20180327750
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Application
    Filed: April 3, 2018
    Publication date: November 15, 2018
    Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Antibodies that bind to MHC class I polypeptide-related sequence A
    Patent number: 10106611
    Abstract: The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to MHC class I polypeptide-related sequence A (MICA).
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: October 23, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, F. Stephen Hodi, Bettina Franz, Kenneth F. May, Jr., Christopher Harvey
  • Methods and compositions for reducing immunosupression by tumor cells
    Patent number: 9944931
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: April 17, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • THERAPEUTIC PEPTIDES
    Publication number: 20170022275
    Abstract: The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to MHC class I polypeptide-related sequence A (MICA).
    Type: Application
    Filed: December 5, 2014
    Publication date: January 26, 2017
    Inventors: Kai W. WUCHERPFENNIG, Glenn DRANOFF, F. Stephen HODI, Bettina FRANZ, Kenneth F. MAY, JR., Christopher HARVEY
  • THERAPEUTIC PEPTIDES
    Publication number: 20170008962
    Abstract: The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 12, 2017
    Inventors: Kai W. WUCHERPFENNIG, Bettina FRANZ, Kenneth F. MAY, JR., Glenn DRANOFF, F. Stephen HODI, Christopher HARVEY
  • VACCINE COMPOSITIONS AND METHODS FOR RESTORING NKG2D PATHWAY FUNCTION AGAINST CANCERS
    Publication number: 20170000867
    Abstract: The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide.
    Type: Application
    Filed: March 16, 2015
    Publication date: January 5, 2017
    Inventors: Glenn Dranoff, Kai W Wucherpfennig, Christopher Harvey, F. Stephen Hodi